The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs
TC Johnstone, K Suntharalingam, SJ Lippard - Chemical reviews, 2016 - ACS Publications
The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,
but new platinum agents have been very slow to enter the clinic. Recently, however, there …
but new platinum agents have been very slow to enter the clinic. Recently, however, there …
Synthetic methods for the preparation of platinum anticancer complexes
JJ Wilson, SJ Lippard - Chemical reviews, 2014 - ACS Publications
The demonstration in the 1960s that cis-diamminedichloroplatinum (II), or cisplatin, inhibits
cellular division of Escherichia coli 1 led to the subsequent discovery that this simple …
cellular division of Escherichia coli 1 led to the subsequent discovery that this simple …
Tumour-inhibiting platinum complexes—state of the art and future perspectives
MA Jakupec, MS Galanski, BK Keppler - Reviews of physiology …, 2003 - Springer
Thirty years after the onset of the first clinical studies with cisplatin, the development of
antineoplastic platinum drugs continues to be a productive field of research. This article …
antineoplastic platinum drugs continues to be a productive field of research. This article …
DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair
V Brabec - 2002 - Elsevier
The development of metal-based antitumor drugs has been stimulated by the clinical
success of cis-diamminedichloroplatinum (II)(cisplatin) and its analogs and by the clinical …
success of cis-diamminedichloroplatinum (II)(cisplatin) and its analogs and by the clinical …
Photoactivatable platinum complexes
PJ Bednarski, FS Mackay… - Anti-Cancer Agents in …, 2007 - ingentaconnect.com
The development of photoactivatable prodrugs of platinum-based antitumor agents is aimed
at increasing the selectivity and hence lowering toxicity of this important class of antitumor …
at increasing the selectivity and hence lowering toxicity of this important class of antitumor …
Current status of trans-platinum compounds in cancer therapy
G Natile, M Coluccia - Coordination Chemistry Reviews, 2001 - Elsevier
Most of the structure/activity rules emerged from the initial studies by Rosenberg and Cleare
and Hoeschele have now been questioned. Specifically:(i) trans compounds are inactive,(ii) …
and Hoeschele have now been questioned. Specifically:(i) trans compounds are inactive,(ii) …
Trans-platinum complexes in cancer therapy
M Coluccia, G Natile - Anti-Cancer Agents in Medicinal …, 2007 - ingentaconnect.com
The research of new platinum drugs active towards cisplatin refractory/resistant tumors has
been mostly focussed on compounds with cis geometry because transplatin, the trans …
been mostly focussed on compounds with cis geometry because transplatin, the trans …
Novel concepts in the development of platinum antitumor drugs
MA Fuertes, J Castilla, C Alonso… - … Chemistry-Anti-Cancer …, 2002 - ingentaconnect.com
The limitations of cisplatin as an anticancer drug have stimulated the search for other
antitumor-active platinum complexes with improved pharmacological properties. The two …
antitumor-active platinum complexes with improved pharmacological properties. The two …
Trans geometry in platinum antitumor complexes
U Kalinowska-Lis, J Ochocki… - Coordination Chemistry …, 2008 - Elsevier
In this paper we summarize the work on the development of trans-platinum complexes as
antitumor agents during the last 15 years. We review the structures and chemical properties …
antitumor agents during the last 15 years. We review the structures and chemical properties …
Current status of the development of trans-platinum antitumor drugs
JM Pérez, MA Fuertes, C Alonso… - Critical reviews in …, 2000 - Elsevier
The discovery in the 1990s of several trans-Pt complexes with in vitro and in vivo activity
against tumor cells sensitive and/or resistant to cisplatin has forced the re-evaluation of the …
against tumor cells sensitive and/or resistant to cisplatin has forced the re-evaluation of the …